Benefits
Selected obstetric indications under supervised care; this label does not establish intranasal social or mood benefits.
Named U.S. presentation only; selected label sections.
Peptide library
Oxytocin
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. The selected PITOCIN parenteral label reports a plasma half-life of approximately 1–6 minutes, shortened in late pregnancy and lactation. Uterine response after IM administration can last hours; effect duration is not plasma half-life. This does not characterize nasal products. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
About this assessment
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Who was studied
The population specified by this product label; other indications and jurisdictions remain outside this check.
What the sources found
Selected obstetric indications under supervised care; this label does not establish intranasal social or mood benefits.
Regulatory scope
U.S. label record for NDA018261. This does not confer authorization on other products using the ingredient name.
What remains unknown
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
How it works
Pitocin oxytocin, 10 units/mL pharmacy bulk package
Consult the product label for pharmacology. A mechanism does not extend its approved indications.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Reported adverse effects
- The label excludes elective labor induction without medical indication; obstetric dosing and monitoring require professional care.
Named U.S. presentation only; selected label sections.
Contraindications
- PITOCIN antepartum contraindications include major cephalopelvic disproportion, undeliverable fetal presentation, emergencies favoring surgery, fetal distress when delivery is not imminent, failure to progress despite adequate contractions, uterine hyperactivity, contraindications to vaginal delivery, and hypersensitivity. Obstetric assessment is essential.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Sources used for this snapshot
Claim-by-claim evidence
Adverseeffects
The label excludes elective labor induction without medical indication; obstetric dosing and monitoring require professional care.
Named U.S. presentation only; selected label sections.
Storage
This 50 mL pharmacy bulk presentation: 20–25°C. Its preparation and access limits cannot be transferred to personal multidose use.
Named U.S. presentation only; selected label sections.
Pharmacokinetics
The selected PITOCIN parenteral label reports a plasma half-life of approximately 1–6 minutes, shortened in late pregnancy and lactation. Uterine response after IM administration can last hours; effect duration is not plasma half-life. This does not characterize nasal products.
Named U.S. product only; label revision 20260506. Educational extraction, not complete clinical review.
Contraindications
PITOCIN antepartum contraindications include major cephalopelvic disproportion, undeliverable fetal presentation, emergencies favoring surgery, fetal distress when delivery is not imminent, failure to progress despite adequate contractions, uterine hyperactivity, contraindications to vaginal delivery, and hypersensitivity. Obstetric assessment is essential.
Named U.S. product only; label revision 20260506. Educational extraction, not complete clinical review.
References
Oxytocin - The Sweet Hormone? 2017.
PMID: 28283319
Pitocin oxytocin, 10 units/mL pharmacy bulk package. U.S. structured product label, effective 20260506. Selected sections only.
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.